Skip to main
AORT

Artivion (AORT) Stock Forecast & Price Target

Artivion (AORT) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Artivion Inc reported a significant improvement in its financial metrics, highlighted by a 320 basis points year-over-year increase in adjusted EBITDA margin and a gross margin of 65.6%, which exceeded estimates by 190 basis points. The company's Preservation Services segment generated $25.7 million, reflecting a 5% growth in the third quarter of 2025, while product sales surged 19%, totaling $87.7 million, driven by strong performances in key categories such as aortic stent grafts and On-X products. Overall, Artivion’s robust product portfolio, ongoing international expansion, and strong revenue growth are expected to foster further margin enhancements, establishing a positive outlook for the company.

Bears say

The financial outlook for Artivion Inc is clouded by several risks that could negatively impact its revenue growth, particularly in relation to the company's reliance on new product approvals and market dynamics. Delays in clinical trials and disappointing sales from new product launches are anticipated to result in slowing revenue growth, with projections estimating mid- to high-single digit increases or lower. Additionally, the company faces significant challenges, including potential tariffs and regulatory changes in international markets that may affect its tissue preservation services revenue, which is a critical component of its overall financial performance.

Artivion (AORT) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Artivion and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Artivion (AORT) Forecast

Analysts have given Artivion (AORT) a Buy based on their latest research and market trends.

According to 7 analysts, Artivion (AORT) has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.69, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.69, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Artivion (AORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.